Company profile: Orgenesis
1.1 - Company Overview
Company description
- Provider of point-of-care platforms, technologies, and networks to develop, produce, and distribute advanced cell and gene therapies, including a novel diabetes treatment that converts liver cells into functional insulin-producing cells. Offers POCare Platform, Therapies, Technologies, and a global POCare Network to lower costs and accelerate market access.
Products and services
- POCare Platform: A point-of-care-integrated platform that architects and unifies development, production, and distribution, simplifying scale-up of advanced therapies, including cell and gene therapies, directly within hospital settings
- POCare Technologies: GMP-compliant customized, automated processing systems that produce scalable therapy manufacturing workflows, developed with technology partners to standardize and automate production of advanced treatments at the point of care
- POCare Network: A hospital-embedded global network of academia, research, and hospital partners that delivers development, production, and distribution of advanced therapies directly at the point of care
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orgenesis
Science Group
HQ: United Kingdom
Website
- Description: Provider of independent advisory and advanced product development services for science and technology initiatives. Through specialist companies Sagentia, Oakland Innovation, OTM Consulting and Leatherhead Food Research, the group collaborates with clients in key vertical markets to deliver clear returns on technology and R&D.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Science Group company profile →
Jubilee Clinical Research
HQ: United States
Website
- Description: Provider of clinical research across diverse indications, including new antibiotic developments and the latest diabetic therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jubilee Clinical Research company profile →
ApiJect
HQ: United States
Website
- Description: Provider of a medical technology platform enabling scalable manufacturing and fill-finish of prefilled, single-dose injectors using Blow-Fill-Seal aseptic packaging. Offers the Prefilled ApiJect Injector with a pen needle–style hub; technology licensing for BFS mold/device design, development and production support; and design and engineering services for BFS fill-finish of temperature-sensitive biologics and vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ApiJect company profile →
Biopta
HQ: United Kingdom
Website
- Description: Provider of human tissue-based contract research services for drug development, using ethically donated fresh human tissues from surgery to predict drug behavior and bridge animal studies and clinical trials. Services include fresh human tissue pharmacology, a digital human tissue assay catalog, Alvetex 3D tissue models, REPROSKIN full-thickness skin, neurite outgrowth models, and clinical lab services with AI-driven biospecimen analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biopta company profile →
Gubra
HQ: Denmark
Website
- Description: Provider of pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs focused on the metabolic space, including obesity, diabetes, NASH, and diabetic complications, with specialization in in vivo pharmacology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gubra company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orgenesis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orgenesis
2.2 - Growth funds investing in similar companies to Orgenesis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orgenesis
4.2 - Public trading comparable groups for Orgenesis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →